415 related articles for article (PubMed ID: 7665978)
1. Thrombotic risk factors and oral contraception.
Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
[TBL] [Abstract][Full Text] [Related]
2. Resistance to activated protein C in women using oral contraceptives.
Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
[TBL] [Abstract][Full Text] [Related]
3. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
4. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
5. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].
Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H
Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
8. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
9. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Svensson PJ; Benoni G; Fredin H; Björgell O; Nilsson P; Hedlund U; Nylander G; Bergqvist D; Dahlbäck B
Thromb Haemost; 1997 Sep; 78(3):993-6. PubMed ID: 9308742
[TBL] [Abstract][Full Text] [Related]
10. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
12. Acquired APC resistance and oral contraceptives: differences between two functional tests.
Curvers J; Thomassen MC; Nicolaes GA; Van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
Br J Haematol; 1999 Apr; 105(1):88-94. PubMed ID: 10233368
[TBL] [Abstract][Full Text] [Related]
13. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
[TBL] [Abstract][Full Text] [Related]
14. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
15. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
16. Thrombophilic mechanisms of OCs.
Comp PC
Int J Fertil Womens Med; 1997; Suppl 1():170-6. PubMed ID: 9168376
[TBL] [Abstract][Full Text] [Related]
17. Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.
Bokarewa MI; Blombäck M
Semin Hematol; 1997 Jul; 34(3):235-43. PubMed ID: 9241708
[TBL] [Abstract][Full Text] [Related]
18. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
Lidegaard O
Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
[TBL] [Abstract][Full Text] [Related]
19. The 1691 G-->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients.
Leroy-Matheron C; Levent M; Pignon JM; Mendonça C; Gouault-Heilmann M
Thromb Haemost; 1996 Jan; 75(1):4-10. PubMed ID: 8713771
[TBL] [Abstract][Full Text] [Related]
20. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
